Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01474174 · ClinicalTrials.gov registry record
Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 38
- Enrollment target
NCT01474174: Completed study, sponsored by Wake Forest University Health Sciences.
NCT01474174 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01474174 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
This pilot clinical trial studies trivalent influenza vaccine in preventing flu in patients with central nervous system (CNS) tumors. Flu vaccine may help the body build an effective immune response and help prevent flu in patients who are receiving chemotherapy for CNS tumors
Primary Outcome
Seroconversion rate will be defined as the percentage of patients with at least a four-fold increase in HI antibodies between baseline and follow up. Seroprotection rate will be defined as the percentage of patients with a serum HI antibody of at least 1:40. The relationship between seroconversion and various clinical variables including therapy status (active vs longterm follow-up), glucorticoid dose and immune function will be measured. Seroconversion and seroprotection rate comparisons will b
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL trivalent influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-07 |
What the finished NCT01474174 record still lists
NCT01474174 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01474174 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01474174 about?
NCT01474174 is a clinical study titled "Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors". This pilot clinical trial studies trivalent influenza vaccine in preventing flu in patients with central nervous system (CNS) tumors. Flu vaccine may help the body build an effective immune response and help prevent flu in patients who are receiving chemotherapy for CNS tumors
What is the current status of trial NCT01474174?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2011-09. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01474174?
The interventions under investigation include: laboratory biomarker analysis (OTHER), trivalent influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01474174?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia